Table 1.
Demographics of three generic groups and the reference group
| Characteristics | Accord | Amarox | Sandoz | Reference | p-value |
|---|---|---|---|---|---|
| Total patients | 107 | 81 | 13 | 150 | |
| Centre (%) | |||||
| NKI | 0 | 81 (100) | 0 | 60 (40.0) | < 0.01 |
| LUMC | 37 (34.6) | 0 | 0 | 24 (16.0) | < 0.01 |
| RadboudUMC | 49 (45.8) | 0 | 0 | 41 (27.3) | < 0.01 |
| UMCG | 21 (19.6) | 0 | 13 (100) | 25 (16.7) | < 0.01 |
| Female sex (%) | 38 (35.5) | 34 (42.0) | 6 (46.2) | 66 (44.0) | 0.56 |
| Median age, years (IQR) | 69 (61–75) | 70 (59–76) | 64 (62–72) | 68 (59–75) | 0.89 |
| Indication (%) | |||||
| Neo-adjuvant | 10 (9.3) | 21 (25.9) | 2 (15.4) | 26 (17.3) | 0.01 |
| Adjuvant | 25 (23.4) | 3 (3.7) | 2 (15.4) | 14 (9.3) | < 0.01 |
| Palliative | 72 (67.3) | 57 (70.4) | 9 (69.2) | 110 (73.3) | 0.77 |
| Daily dosea | |||||
| < 400 mg | 10 (9.3) | 10 (12.3) | 0 (0) | 16 (10.7) | 0.70 |
| 400 mg | 81 (75.7) | 45 (55.6) | 12 (92.3) | 99 (66.0) | 0.01 |
| > 400 mg | 16 (15.0) | 26 (32.1) | 1 (7.7) | 35 (23.3) | 0.02 |
| Treatment duration in months (IQR)b | 30 (18–71) | 33 (19–91) | 23 (6–66) | 34 (12–81) | 0.44 |
| Total AEs before switch (IQR)c | 4 (2–6) | 4 (3–7) | 4 (3–5) | 3 (2–6) | 0.31 |
aDosage at date of the switch
bRepresents the median duration of treatment until the switch
cThe median number of imatinib-related adverse events that occurred during full treatment before the switch
NKI Netherlands Cancer Institute, LUMC Leiden University Medical Center, RadboudUMC Radboud University Medical Center, UMCG University Medical Center Groningen, AEs adverse events